Keros Therapeutics (KROS) Cash from Financing Activities (2019 - 2025)
Keros Therapeutics (KROS) reported Cash from Financing Activities of -$378.63 million for Q4 2025, compared with $75.54 million a year earlier.
Powered by 
Analysis
Keros Therapeutics (KROS) Cash from Financing Activities (2019 - 2025) Analysis & Trends
For FY2025, Keros Therapeutics posted Cash from Financing Activities of -$378.47 million.
- By year, Cash from Financing Activities came in at $391.82 million in FY2024 (+118.9%), $178.96 million in FY2023 (+48.7%), $120.31 million in FY2022 (+321.4%) and $28.55 million in FY2021 (-90.4%).
- The Q4 2025 figure ranks as the lowest quarterly Cash from Financing Activities in data going back to Q2 2019.
- Year over year, Cash from Financing Activities gained in three of the last six quarters, with an average decline of 23.6%.
- The high point for year-over-year Cash from Financing Activities in five years was Q3 2021 (growth of 288.9%); the low point was Q1 2025 (a decline of 100.0%).
- Per Business Quant data, the three quarters before Q4 2025 came in at $140,000 (Q3 2025), $17,000 (Q2 2025) and $4,000 (Q1 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,172.05 Bn | 1,140.63 Bn | 19.71 Bn | 8.43 Bn |
| 2 | Johnson & Johnson | 636.25 Bn | 554.77 Bn | 17.26 Bn | -8.78 Bn |
| 3 | AbbVie | 503.38 Bn | 476.49 Bn | 12.70 Bn | -5.05 Bn |
| 4 | Merck | 377.92 Bn | 332.30 Bn | 12.21 Bn | 1.76 Bn |
| 5 | Novartis Ag | 304.19 Bn | 268.18 Bn | 11.24 Bn | -2.02 Bn |
| 6 | Astrazeneca | 267.24 Bn | 240.93 Bn | 12.86 Bn | -3.89 Bn |
| 7 | Amgen | 242.06 Bn | 197.46 Bn | 7.24 Bn | -1.48 Bn |
| 8 | Gilead Sciences | 193.78 Bn | 167.97 Bn | 6.22 Bn | 2.34 Bn |
| 9 | Pfizer | 172.54 Bn | 119.18 Bn | 10.94 Bn | -3.66 Bn |
| 10 | Keros Therapeutics | 224.04 Mn | -1.70 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -378.63 Mn |
| Sep 30, 2025 | 140,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | 75.54 Mn |
| Sep 30, 2024 | 155.94 Mn |
| Jun 30, 2024 | 3.53 Mn |
| Mar 31, 2024 | 156.80 Mn |
| Dec 31, 2023 | 69.25 Mn |
| Sep 30, 2023 | 284,000.00 |
| Jun 30, 2023 | 1.74 Mn |
| Mar 31, 2023 | 107.68 Mn |
| Dec 31, 2022 | 61.42 Mn |
| Sep 30, 2022 | 48.58 Mn |
| Jun 30, 2022 | 10.19 Mn |
| Mar 31, 2022 | 118,000.00 |
| Dec 31, 2021 | 28.42 Mn |
| Sep 30, 2021 | 35,000.00 |
| Jun 30, 2021 | 57,000.00 |
| Mar 31, 2021 | 42,000.00 |
API Access
Keros Therapeutics Cash from Financing Activities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=KROS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-from-financing-activities", "ticker": "KROS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=KROS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();